July 09, 2018
1 min read

Transplantation of HCV-infected kidney reduces cost, improves life expectancy in HCV patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Kidney transplant with a kidney infected with hepatitis C virus, followed by treatment for the hepatitis C, was effective and reduced costs compared with transplant with an uninfected kidney after hepatitis C treatment, according to new research published in Annals of Internal Medicine.

“Between 10% to 15% of U.S. patients receiving dialysis are seropositive for [HCV],” the researchers wrote. “Some of these patients are willing to accept HCV-infected kidneys from deceased donors in part because wait times for such kidneys are shorter than those for HCV-uninfected kidneys.”

Researchers compared the quality-adjusted life years (QALYs) and cost of kidney transplants among patients with HCV who received an HCV-infected kidney, then HCV treatment, and patients who received HCV treatment, then an HCV-uninfected kidney.

They found that transplanting an HCV-infected kidney decreased QALYs due to increased lifetime probability of death from end-stage liver disease by 5%, compared with an increase of 3.4% for receiving an HCV-uninfected kidney. Transplant of an HCV-uninfected kidney also led to a decrease in QALYs related to chronic kidney disease; however, there was a 34.5% increase in death from chronic kidney disease among recipients of HCV-uninfected kidneys, vs. a 29% increase among recipients of HCV-infected kidneys. Researchers noted that this difference was due to increased duration of dialysis while waiting for an uninfected kidney.

The researchers also found that transplant of an HCV-infected kidney followed by HCV treatment was less costly than transplant of an HCV-uninfected kidney, due to wait times. An average patient gained 0.5 QALY at a lifetime cost savings of $41,591, when receiving an HCV-infected kidney.

“In an era of increasing success for kidney transplants and demand that far outstrips supply, deferring antiviral therapy until after transplant of HCV-infected kidneys, when available, should be both cost-saving and effective,” the researchers wrote. – by Jake Scott


Disclosure: Eckman reports grants from Merck during the conduct of the study. Please see the study for all authors’ relevant financial disclosures.